Drug
Leo 138559
Leo 138559: highest development phase Phase 2, developed by LEO Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| LEO 138559 NCT05923099 | Phase 2 | Atopic Dermatitis |
Latest
No recent events.
Follow Leo 138559 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.